“As the first STAT6-targeted agent in clinical development, we believe KT-621 has the opportunity to dramatically alleviate the burden of disease for those suffering from AD by offering an ...

Speaking of Sanofi, Nurix is working with this big pharma to develop a STAT6 protein degrader to target TH2-mediated inflammatory disorders, such as Asthma, Atopic Dermatitis, and Allergies.

SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad ...

“GS-6791/NX-0479 is one drug candidate emerging from Nurix’s growing pipeline of degrader-based medicines designed to treat inflammation and autoimmune diseases, including our STAT6 degrader ...

2014). The team then leveraged this finding to identify developmental processes where BMP4 homodimers are specifically required. They created mice that expressed BMP4 S91C or BMP4 E93G. Embryos ...

Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock – anytime.

“As the first STAT6-targeted agent in clinical development, we believe KT-621 has the opportunity to dramatically alleviate the burden of disease for those suffering from AD by offering an effective ...

Marfan syndrome (MFS) is a heritable connective tissue disorder caused by mutations in the Fibrillin‐1 gene, which encodes the extracellular matrix protein fibrillin‐1. Patients with MFS are ...